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Abstract Hypertrophic cardiomyopathy, a common,
inherited cardiac muscle disease, is primarily caused by
mutations in sarcomeric protein-encoding genes and is
characterized by overgrowth of ventricular muscle that is
highly variable in extent and location. This variability has
been partially attributed to locus and allelic heterogeneity
of the disease-causing gene, but other factors, including
unknown genetic factors, also modulate the extent of
hypertrophy that develops in response to the defective
sarcomeric functioning. Components of the renin-angio-
tensin-aldosterone system are plausible candidate
hypertrophy modiﬁers because of their role in controlling
blood pressure and biological effects on cardiomyocyte
hypertrophy.
Introduction
We investigated four Single Nucleotide Polymorphisms in
the gene-encoding angiotensin converting enzyme 2
(ACE2), a gene on the X-chromosome whose RAAS
product modulates cardiac structure and function, for
association with hypertrophic traits in 227 individuals
belonging to 22 HCM families with known founder dis-
ease-causing mutations.
After adjustment for hypertrophy-inﬂuencing factors,
including the particular disease-causing mutation, we ﬁnd
association between the G-allele of rs879922 and increased
left ventricular mass (effect size: 18.7 g), maximum in-
terventricular septal thickness (effect size: 1.9 mm) as well
as maximum posterior wall thickness (effect size: 0.7 mm).
These data demonstrate that ACE2 plays a role in
modifying the extent of hypertrophy that develops in HCM,
independent of the effect of the disease-causing mutation
or blood pressure.
Hypertrophic cardiomyopathy (HCM; OMIM #192600)
is a primary cardiac muscle disorder classically caused by
mutations ([400) in genes encoding components of the
thick and thin ﬁlaments of the cardiac sarcomere (http://
genetics.med.harvard.edu/*seidman/cg3/index.html). Ext-
reme variability of the hypertrophic phenotype is a hallmark
feature of HCM and has been attributed in part to allelic
effects of the disease-causing gene. Evidence from human
and transgenic animal studies indicates that the degree of
hypertrophythatdevelopsinresponsetothecausalmutation
is modiﬁed by environmental factors (including demo-
graphic factors such as age, sex and body size), as well as by
other genetic factors (Semsarian et al. 2001).
Genes within the renin-angiotensin-aldosterone system
(RAAS) have been investigated as modiﬁers of the
hypertrophic variability in HCM in recent years (Marian
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DOI 10.1007/s00439-008-0524-62002; Ortlepp et al. 2002), and much emphasis has been
placed on the possible role of the angiotensin-converting-
enzyme (ACE) I in the development of hypertrophy.
However, subsequently, a second ACE, ACEII, has been
discovered and its product, viz. angiotensin-(1-7), has been
found to antagonize the vasoconstriction mediated by its
substrate, angiotensin II. Lieb et al. found that minor alleles
of four single nucleotide polymorphisms (SNPs) in the X-
chromosomally located ACEII gene (ACE2) were associ-
ated with increases in hypertrophic parameters, viz. left
ventricular mass indexed to body size (LVMI), as well as
end-diastolic interventricular septal wall thickness (IVS) in
males, but not in females (Lieb et al. 2006). Subsequently,
Wang et al. also reported that minor alleles of other SNPs
in ACE2 were again associated with increased IVS in male
but not female HCM patients (Wang et al. 2008). In the
latter study, it is possible that the effect of the unknown
HCM-causing mutations in the case cohort could confound
the results. Hence, we aimed to investigate the role of
ACE2 variants in the extent of hypertrophy that develops in
genotype-known HCM patients belonging to families in
which any of three South African HCM founder mutations
segregate.
Methods
Subjects
The study was approved by the University of Stellenbosch
Health Sciences Faculty’s Institutional Review Board
(N04/03/062). Twenty-two consecutively referred index
cases bearing one of the previously reported South African
HCM-founder mutations (7 R92WTNNT2, 3 R403WMYH7
and 11 A797TMYH7) were identiﬁed and pedigree tracing
was performed (Revera et al. 2008). Individuals who gave
informed written consent were tested for carrier-status for
each of the three founder mutations, as previously descri-
bed (Moolman-Smook et al. 1999).
Clinical evaluation
Blood pressure was taken, twice: in the sitting position,
after 5 min of bed rest, and the second measurement was
used. Individuals were coded as hypertensive if they had
systolic blood pressure C140 mm Hg, or diastolic blood
pressure C90, or were on anti-hypertensive medication.
Medical history, and demographic data (age, sex, height,
weight) were recorded for each participant. We performed
standard electrocardiography on a MAC1200ST after
5 min of rest in the supine position, and from this derived
resting heart rate. Echocardiography was performed anew
on all participating individuals, using a standardized
procedure to measure the wall thickness in 16 left ven-
tricular wall segments, by a single experienced
echocardiographer (MR) who was blinded to mutation
status, according to recommendations of the American
Society of Echocardiography (Schiller et al. 1989), as
previously described (Revera et al. 2008). LVM was cal-
culated using the American Society of Echocardiography’s
recommended formula for estimation of LVM from 2D-LV
linear dimensions:
LVM¼0:8
  1:04 LVIDdþPWTdþSWTd ðÞ
3  LVIDd ðÞ
3
hi   
þ0:6g:
ACE2 genotyping
As the LD structure of this (and other) regions of the
genome has not been reported in the study population, we
relied on density selection of SNPs. Four polymorphisms,
viz. rs1978124 (intron 1), rs2285666 (intron 3), rs879922
(intron 11) and rs4646179 (exon 16), spread through the
length of ACE2 at an average spacing of *8 kb, were
selected from dbSNP. These SNPs were chosen because
they had been validated by frequency, had been found
associated with cardiovascular traits in previous studies
(Lieb et al. 2006; Liu et al. 2005; Yang et al. 2006) and
were amenable to genotyping by means of restriction
enzyme analysis.
ACE2 genomic regions containing the variants of
interest were PCR ampliﬁed from subjects’ genomic DNA
using standard methodology (Moolman-Smook et al.
1999); primers and annealing temperature used are given in
Table 1. Variants were genotyped by allele-speciﬁc
restriction enzyme digestion of the PCR amplicons and
fragment sizes detected by gel electrophoresis (Table 1).
Two independent observers, blinded to phenotypic data,
performed allele-calling. Ten percent of samples, randomly
selected for each amplicon, were nucleotide sequenced to
verify genotyping results. Furthermore, Mendelian inheri-
tance within families was assessed by Pedstats, using X-
chromosome settings, and inconsistencies were resolved by
re-genotyping.
Statistical analyses
Quantile normalization was used to convert each trait to
approximate normality (Pilia et al. 2006). Associations of
ACE2 variants with heritable hypertrophy traits, viz. left
ventricular mass (LVM), maximum interventricular septal
thickness (maxIVS) and maximum posterior wall thickness
(maxPW), were assessed with specialized mixed-effects
models utilizing per-individual random effects which are
correlated according to kinship coefﬁcients (R package
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123kinship, function lmekin). These models include variance
components for environment and polygenes. Furthermore,
concomitant adjustment was made for factors known to
inﬂuence cardiac hypertrophy, viz. age, sex, body surface
area, heart rate, systolic and diastolic blood pressure,
hypertension diagnosis, as well as the identity of the dis-
ease-causing mutation, by including these as covariates in
the analyses. We then formally tested the interaction
between sex and genotype, after modeling the genotypes as
the number of minor alleles (additive term), and a domi-
nance term, which was only non-zero for heterozygous
females (Cordell and Clayton 2005). This model is
equivalent to modeling the genotypes as categories, label-
ing the male genotypes differently to the female genotypes.
When the interaction between sex and genotype was not
statistically signiﬁcant, it was discarded from the model.
The dominance term was similarly discarded if not sig-
niﬁcantly different from zero. The resulting models are
summarized and discussed.
As effect sizes derived from analysis of transformed
data cannot be interpreted in terms of the original mea-
surement units, we also modeled the raw data in terms of
the genotypes of the associated variant rs879922, with
adjustment for confounders and to obtain informative
effect sizes. Because there were only two GG homozygotes
in the group, we combined them with the heterozygotes to
estimate the effect of at least one G-allele.
Linkage disequilibrium between the four markers and
Hardy–Weinberg equilibrium in the study cohort was
assessed by Haploview vs3.32.
Results
Three hundred and twenty individuals belonging to 7
R92WTNNT2, 3 R403WMYH7 and 12 A797TMYH7 families
were genotyped for variants in ACE2; of these, 227 indi-
viduals, including all HCM mutation-carriers, consented to
clinical investigation; clinical and demographic traits of
these individuals are summarized in Table 2.
All markers were in Hardy–Weinberg equilibrium in the
unrelated individuals and there was no relevant correlation
between the SNPs (all r
2 B 0.1). Genotype frequencies of
the markers in the study population are given in Table 3.
Statististically, there were no signiﬁcant interactions
between sex and genotype, so that no sex-speciﬁc effects of
alleles were observed (results not shown). As the domi-
nance term was not signiﬁcantly different from zero, we
could model the genotypes as single numerical factors,
speciﬁed as the number of minor-alleles carried by the
individual; thus males had a maximum of one of these
alleles and females a maximum of two (‘‘additive’’ coding)
(Cordell and Clayton 2005). The P values for signiﬁcance
Table 2 Basic statistics of relevant clinical and demographic traits in
the study cohort, stratiﬁed by HCM-mutation status
HCM-mutation bearers Controls
N = 127 N = 100
Median (Q1,Q3) Median (Q1,Q3)
Age (years) 41 (25,53) 41 (29,51)
BSA (kg/m
2) 1.8 (1.6,2.0) 1.8 (1.7,2.0)
SystBP (mm Hg) 120 (110,130) 120 (110,130)
DiastBP (mm Hg) 80 (70,80) 80 (70,90)
Heart rate (bpm) 66 (60,75) 69 (62,76)
LVM (g) 166 (125,218) 126 (103,158)
mIVST (mm) 13.9 (10.4,19.6) 10.2 (9.0,11.3)
mPW (mm) 10.1 (9.0,11.6) 9.0 (8.0,9.7)
Because of the skewness of some distributions, data are summarised
here as median (interquartile range), and were quantile normalized
prior to association analysis
(Q1,Q 3) = Q1, ﬁrst quartile, Q3, third quartile; BSA, body surface
area; Syst, systolic; BP, blood pressure; Diast, diastolic; bpm, beats
per minute; LVM, left ventricular mass; g, grams; mIVST, maximum
interventricular septal thickness; mm, millimeter; mPW, maximum
posterior wall thickness
Table 1 Summary of PCR-based allele-speciﬁc restriction enzyme analysis used for genotyping of ACE2 variants
Variant Primers (50–30) Restriction
enzyme
Amplicon
size (bp)
Major allele
sizes (bp)
Minor allele
sizes (bp)
Detection method
rs1978124 F: tcttcctggctccttctcagc Sau96I 1,044 T (1044) C (962, 82) 1.5% Agarose electrophoresis
R: accacaatggcagagaaaggg
rs2285666 F: gtttgtaacccagataatcc AluI 130 C (130) T (78, 52) 12% PAGE
R: gttgaaacacacatatctgc
rs879922 F: ttgtgttaagatcttgtccc BfaI 188 C (188) G (146, 42) 12% PAGE
R: aataaactgagctccagc
rs4646179 F: tacagggaggaggatgtgcg HpyCH4IV 680 T (328, 229, 123) C (328, 152, 123, 77) 2.5% Agarose electrophoresis
R: tgatggcaatacctgtccacg
bp base pairs, PAGE polyacrylamide gel electrophoresis
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123tests of the additive term, after removing the dominance
term from the model, are shown in Table 4. While there
was no evidence for association between hypertrophy traits
and ACE2 SNPs rs1978124, rs2285666 or rs4646179, the
G-allele of rs879922 was found to have a signiﬁcant effect
on all three of the investigated hypertrophic traits,
increasing each by a modest amount. The effect sizes of the
G-allele on untransformed, covariate-adjusted traits were
18.7 g for LVM, 1.9 mm for maxIVS and 0.7 mm for
maxPW (Table 4).
Discussion
In this study, we used HCM families, in which the disease is
caused by deﬁned founder mutations, to assess the role of
variants in ACE2 in hypertrophy development, independent
of factors that are known to inﬂuence this phenomenon. We
ﬁndthattheG-alleleofrs879922isassociatedwithincreased
hypertrophy, viz. increased LVM, maxIVS and maxPW.
Lieb et al. previously reported association of the
rs879922 G-allele, singly as well as within a four-marker
haplotype (with rs4646156, rs4240157 and rs233575), with
modestly increased LVM and maxIVS in the general male
population in Augsburg, Germany (Lieb et al. 2006). Wang
et al. recently reported association of other ACE2 variants,
rs2106809 and rs663677, with maxIVS, again only in a
group of male HCM patients, with unknown primary dis-
ease-causing mutations (Wang et al. 2008).
Although ACE2 maps to a hypertension quantitative trait
locus identiﬁed in three different rat models of hyperten-
sion, no association between ACE2 variants and
hypertension has been found to date (Benjaﬁeld et al. 2004;
Lieb et al. 2006; Wang et al. 2008). In our study, associ-
ation with hypertrophy was also independent of blood
pressure per se or diagnosis of hypertension.
Taken together, our data indicate a role for variation in
ACE2 in modifying the development of left ventricular
hypertrophy. Furthermore, the results suggest that the
genetic modiﬁers of the cardiac hypertrophy that develops
in response to a primary HCM-causing mutation may also
be involved in hypertrophy development in the general
population. The effect size of the G-allele of rs879922 is
modest, as has been previously described for other RAAS
gene variants (Mayosi et al. 2003), which may suggest that
the hypertrophic phenotype is the cumulative result of a
number of genes of moderate effect. As rs879922 occurs
within an intron and does not have any obvious functional
role, it is possible that the association noted in this study, as
well as that of Lieb et al., indicates the effect of a func-
tional variant in linkage disequilibrium with rs879922. The
extent of variation in this gene and the LD distribution
across the genome in the study population is unknown.
However, rs879922 tags at least 2–8 additional HAPMAP
SNPs in the CEU, YRI and JPT + CHB populations. In the
CEU and YRI HAPMAP populations, variation in ACE2 is
predominantly captured by two and three haplotype blocks,
respectively; rs879922 is located within a haplotype block
involving the 30 approximately third of the gene, which
may indicate that the functional variant lies in this region
of the gene.
Due to the highly variable distribution of left ventricular
hypertrophy in HCM, it is difﬁcult to distinguish a single
echocardiographic measure that accurately quantiﬁes the
extent of hypertrophy in all patients. Although LVM is most
often used to quantify hypertrophy in HCM, it is known to
be an inaccurate measure when echocardiographically
derived, due to the asymmetric nature of hypertrophy in
HCM. Thus, we also investigated hypertrophic traits that
Table 4 Effect size (beta), standard error (SE) and P value for tests of association of variants in ACE2
SNP LVMecho max IVST max PW
Beta SE P value Beta SE P value Beta SE P value
rs1978124 -8.0 5.9 0.1190 -1.14 0.62 0.2448 -0.315 0.234 0.0772
rs2285666 6.7 8.5 0.6544 0.02 0.80 0.7796 -0.246 0.276 0.1825
rs879922 18.7 9.4 0.0205 1.87 0.87 0.0393 0.657 0.305 0.0090
rs4646179 26.9 27.0 0.4813 3.71 2.56 0.2999 0.154 0.893 0.6102
Effect size and standard error are given in original units of measurement for traits, for ease of interpretation, while P values are for tests on
quantile normalised traits. Beta is the effect on the trait of adding a G-allele
LVM left ventricular mass, maxIVST maximum interventricular septal thickness, maxPW maximum posterior wall thickness
Table 3 Genotype frequencies for ACE2 variants in the complete
study cohort, stratiﬁed by gender
Male Female
C G CC CG GG
rs1978124 0.38 0.62 0.16 0.31 0.53
rs2285666 0.81 0.19 0.59 0.38 0.03
rs879922 0.77 0.23 0.50 0.49 0.01
rs4646179 0.98 0.02 0.98 0.02 0.00
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123are heritable (Mayosi et al. 2002) and can be directly
measured, viz. maxIVS and maxPW, rather than calculated
from geometric assumptions.
We did not employ Bonferroni correction for multiple
testing, as the traits investigated are highly correlated, and
such correction is considered over-conservative, risking the
rejection of important ﬁndings, while Bayesian methods for
correction rely on knowledge of prior probability of
involvement, which is currently unknown for most genetic
variants (Campbell and Rudan 2002). However, even if the
over-stringent Bonferroni correction for four independent
tests (for the four markers) were performed, the association
noted for rs879922 with maxPW would remain signiﬁcant,
and that with LVM remain a trend.
Although the number of subjects assessed in this study is
modest, our data adds to previous investigations in con-
ﬁrming the involvement of ACE2 in the development of
cardiac hypertrophy, independent of blood pressure or
indeed other hypertrophy covariates, in HCM patients.
Furthermore, in our study, the use of data derived from
HCM families carrying known, founder mutations afforded
beneﬁts over case-control studies, such as additional con-
trol of genotyping accuracy, control over the variability
introduced by distinct primary disease-causing mutations,
and avoidance of the confounding effect of occult popu-
lation stratiﬁcation. Furthermore, our study combined with
that of Lieb et al. and Wang et al. supports a more con-
sistent role for the recently identiﬁed component of RAAS,
ACEII, than the discordant ﬁndings for the original ACEI,
in modulating cardiac hypertrophy, and in particular in
modifying the extent of hypertrophy that develops in
response to HCM-causing mutations.
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